NCT02937662View on ClinicalTrials.gov

Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Idarubicin

Idarubicin at a dose of 10 mg/㎡/d on days 1-3.

DRUG

Cytarabine

Cytarabine at a dose of 100mg/㎡/d on days 1-7.

DRUG

Cyclophosphamide

Cyclophosphamide at a dose of 350mg/㎡/d on the second day and the fifth day.

DRUG

Physician-Directed Regimens without Cyclophosphamide

Regimen without cyclophosphamide including FLA±G regimen, DA regimen, AAG regimen, decitabine with AA regimen.

Trial Locations (1)

Unknown

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT02937662 - Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML | Biotech Hunter | Biotech Hunter